NCT00756717 2019-09-04
MK-0752
Loyola University
Phase 4 Completed
Clinical Trials
3 trialsHas results × 3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid × Clear all
NCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00645333 2014-04-04
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed